{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:09:42Z","timestamp":1784779782398,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Seventeen years after the start of the IBAARV (Beninese initiative for access to antiretrovirals), transmitted drug resistance mutations in ARV-na\u00efve patients and HIV-1 genetic diversity were investigated in Benin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Drug resistance mutations were detected in (27\/248; 10.9%) according to the WHO SDRM 2009 list, with a predominance of mutations directed against NNRTIs drugs (24\/248; 10%). Phylogenetic and recombination analyses showed a predominance of CRF02_AG strains (165\/248; 66.5%) and a high genetic diversity with five other variants and 39 URFs (15.7%) which contained portions of strains that co-circulate in Benin. Eight recent transmission chains revealed active ongoing transmission of HIV-1 strains among ARV-na\u00efve patients. Our study showed a moderate primary drug resistance mutations rate and also provided recent data on the HIV-1 variants that circulate in Benin. Regular monitoring of primary drug resistance is required to adapt HIV-1 treatment strategies and adoption of new WHO recommendations in Benin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-05151-w","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:25:31Z","timestamp":1593667531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin"],"prefix":"10.1186","volume":"13","author":[{"given":"Edmond","family":"Tchiakpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene K.","family":"Keke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Ahoussinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sekpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermione G.","family":"Dagba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gbaguidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Tonoukouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldric","family":"Afangnihoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Bachabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore A.","family":"Gangbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halimatou","family":"Diop-Ndiaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coumba","family":"Toure-Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"5151_CR1","unstructured":"Onusida. www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDSFactSheet_fr.pdf. 2019."},{"key":"5151_CR2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1097\/01.aids.0000131358.29586.6b","volume":"1811","author":"R Kantor","year":"2004","unstructured":"Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, Nguyen DP, Katzenstein D, Fessel WJ. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;1811:1503\u201311.","journal-title":"AIDS."},{"key":"5151_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1086\/427212","volume":"403","author":"RM Novak","year":"2005","unstructured":"Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;403:468\u201374.","journal-title":"Clin Infect Dis"},{"key":"5151_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","volume":"1110","author":"RL Hamers","year":"2011","unstructured":"Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;1110:750\u20139.","journal-title":"Lancet Infect Dis"},{"key":"5151_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1186\/s13104-018-3804-9","volume":"111","author":"AE Mbange","year":"2018","unstructured":"Mbange AE, Kaba D, Diouara AAM, Diop-Ndiaye H, Ngom-Ngueye NF, Dieng A, Lo S, Toure KN, Fall M, Mbacham WF, Diallo MS, Cisse M, Mboup S, Kane CT. Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea. BMC Res Notes. 2018;111:723.","journal-title":"BMC Res Notes."},{"key":"5151_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1089\/aid.2017.0134","volume":"3312","author":"RA Murphy","year":"2017","unstructured":"Murphy RA, Court R, Maartens G, Sunpath H. Second-line antiretroviral therapy in sub-saharan africa: it is time to mind the gaps. AIDS Res Hum Retroviruses. 2017;3312:1181\u20134.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"5151_CR7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350801300502","volume":"135","author":"RL Hamers","year":"2008","unstructured":"Hamers RL, Derdelinckx I, van Vugt M, Stevens W, de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antiviral therapy. 2008;135:625\u201339.","journal-title":"Antiviral therapy."},{"key":"5151_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/135965350901400313","volume":"143","author":"AF Aghokeng","year":"2009","unstructured":"Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, Mokondji E, Nambei WS, Peyou-Ndi MM, Moka JJ, Delaporte E, Peeters M. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antiviral Ther. 2009;143:401\u201311.","journal-title":"Antiviral Ther"},{"key":"5151_CR9","doi-asserted-by":"publisher","first-page":"797463","DOI":"10.5402\/2011\/797463","volume":"2011","author":"S Mamadou","year":"2011","unstructured":"Mamadou S, Hanki Y, Ali Maazou AR, Aoula B, Diallo S. Genetic Diversity and Drug Resistance Mutations in HIV-1 from Untreated Patients in Niamey, Niger. ISRN Microbiol. 2011;2011:797463.","journal-title":"ISRN Microbiol"},{"key":"5151_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.meegid.2009.04.002","volume":"94","author":"DA Yaotse","year":"2009","unstructured":"Yaotse DA, Nicole V, Roch NF, Mireille PD, Eric D, Martine P. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. Infect Genet Evol. 2009;94:646\u201352.","journal-title":"Infect Genet Evol"},{"key":"5151_CR11","first-page":"380","volume":"35","author":"K Bakhouch","year":"2009","unstructured":"Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, Abidi O, Hassar M, Wakrim L. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Countr. 2009;35:380\u201391.","journal-title":"J Infect Dev Countr"},{"key":"5151_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/jmv.23244","volume":"845","author":"L Ceccarelli","year":"2012","unstructured":"Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, Takou D, Nanfack A, Dori L, Torimiro J, Sarmati L, Andreoni M, Perno CF, Colizzi V, Cappelli G. Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. J Med Virol. 2012;845:721\u20137.","journal-title":"J Med Virol"},{"key":"5151_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/sextrans-2011-050209","volume":"883","author":"A Chamberland","year":"2012","unstructured":"Chamberland A, Diabate S, Sylla M, Anagounou S, Geraldo N, Zannou DM, Labbe AC, Worobey M, Alary M, Tremblay C. Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options. Sexually Trans Infect. 2012;883:179\u201383.","journal-title":"Sexually Trans Infect"},{"key":"5151_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jmv.23778","volume":"861","author":"AA Diouara","year":"2014","unstructured":"Diouara AA, Diop-Ndiaye H, Kebe-Fall K, Tchiakpe E, Ndiaye O, Ayouba A, Peeters M, Mboup S, Kane CT. Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal. J Med Virol. 2014;861:45\u201351.","journal-title":"J Med Virol"},{"key":"5151_CR15","doi-asserted-by":"publisher","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","volume":"43","author":"DE Bennett","year":"2009","unstructured":"Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;43:e4724.","journal-title":"PLoS ONE"},{"key":"5151_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/molbev\/msp259","volume":"272","author":"M Gouy","year":"2010","unstructured":"Gouy M, Guindon S, Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010;272:221\u20134.","journal-title":"Mol Biol Evol"},{"key":"5151_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/JVI.73.1.152-160.1999","volume":"731","author":"KS Lole","year":"1999","unstructured":"Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;731:152\u201360.","journal-title":"J Virol"},{"key":"5151_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00002030-200403260-00002","volume":"185","author":"S Hue","year":"2004","unstructured":"Hue S, Clewley JP, Cane PA, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS. 2004;185:719\u201328.","journal-title":"AIDS."},{"key":"5151_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/dky382","volume":"741","author":"A Keita","year":"2019","unstructured":"Keita A, Sereme Y, Pillet S, Coulibaly S, Diallo F, Pozzetto B, Thiero TA, Bourlet T. Impact of HIV-1 primary drug resistance on the efficacy of a first-line antiretroviral regimen in the blood of newly diagnosed individuals in Bamako, Mali. J Antimicrob Chemother. 2019;741:165\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"5151_CR20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1468-1293.2009.00806.x","volume":"116","author":"A Haidara","year":"2010","unstructured":"Haidara A, Chamberland A, Sylla M, Aboubacrine SA, Cisse M, Traore HA, Maiga MY, Tounkara A, Nguyen VK, Tremblay C. High level of primary drug resistance in Mali. HIV Med. 2010;116:404\u201311.","journal-title":"HIV Med"},{"key":"5151_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/jmv.21600","volume":"8110","author":"DM Tebit","year":"2009","unstructured":"Tebit DM, Sangare L, Tiba F, Saydou Y, Makamtse A, Somlare H, Bado G, Kouldiaty BG, Zabsonre I, Yameogo SL, Sathiandee K, Drabo JY, Krausslich HG. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. J Med Virol. 2009;8110:1691\u2013701.","journal-title":"J Med Virol"},{"key":"5151_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/aid.2012.0118","volume":"291","author":"AI Maiga","year":"2013","unstructured":"Maiga AI, Fofana DB, Maiga AC, Diallo F, Ait-Arkoub Z, Daou F, Cisse M, Sarro YD, Oumar AA, Sylla A, Katlama C, Taiwo B, Murphy R, Tounkara A, Marcelin AG, Calvez V. Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Segou and Bamako, Mali. AIDS Res Human Retroviruses. 2013;291:182\u20136.","journal-title":"AIDS Res Human Retroviruses."},{"key":"5151_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3851\/IMP1754","volume":"163","author":"C Charpentier","year":"2011","unstructured":"Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vezinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antiviral Ther. 2011;163:429\u201333.","journal-title":"Antiviral Ther"},{"key":"5151_CR24","first-page":"114","volume":"36","author":"FF Monleau","year":"2011","unstructured":"Monleau FF, Affolabi D, Afangnihoun A, Boillot F, Anagonou S, Peeters M, Delaporte E. Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin. J AIDS HIV Res. 2011;36:114\u201320.","journal-title":"J AIDS HIV Res"},{"key":"5151_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","volume":"3689534","author":"CF Gilks","year":"2006","unstructured":"Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;3689534:505\u201310.","journal-title":"Lancet"},{"key":"5151_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350701200102","volume":"121","author":"M Sturmer","year":"2007","unstructured":"Sturmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine\/lamivudine\/abacavir as a first-line regimen. Antiviral Ther. 2007;121:25\u201330.","journal-title":"Antiviral Ther"},{"issue":"Suppl 2","key":"5151_CR27","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/infdis\/jit107","volume":"207","author":"MC Hosseinipour","year":"2013","unstructured":"Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis. 2013;207(Suppl 2):S49\u201356.","journal-title":"J Infect Dis"},{"key":"5151_CR28","unstructured":"Annemarie M. Wensing M, PhD; Vincent Calvez, MD, PhD; Francesca Ceccherini-Silberstein, PhD; Charlotte Charpentier, PharmaD, PhD; Huldrych F. G\u00fcnthard, MD; Roger Paredes, MD, PhD; Robert W. Shafer, MD; Douglas D. Richman, MD. Update of the Drug Resistance Mutations in HIV-1. 2019; 273."},{"key":"5151_CR29","doi-asserted-by":"publisher","first-page":"e1006000","DOI":"10.1371\/journal.ppat.1006000","volume":"131","author":"JO Wertheim","year":"2017","unstructured":"Wertheim JO, Kosakovsky Pond SL, Forgione LA, Mehta SR, Murrell B, Shah S, Smith DM, Scheffler K, Torian LV. Social and genetic networks of HIV-1 transmission in New York City. PLoS Pathog. 2017;131:e1006000.","journal-title":"PLoS Pathog"},{"key":"5151_CR30","doi-asserted-by":"publisher","first-page":"e1006895","DOI":"10.1371\/journal.ppat.1006895","volume":"142","author":"D Kuhnert","year":"2018","unstructured":"Kuhnert D, Kouyos R, Shirreff G, Pecerska J, Scherrer AU, Boni J, Yerly S, Klimkait T, Aubert V, Gunthard HF, Stadler T, Bonhoeffer S. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathog. 2018;142:e1006895.","journal-title":"PLoS Pathog"},{"key":"5151_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/infdis\/jit345","volume":"2089","author":"H Castro","year":"2013","unstructured":"Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;2089:1459\u201363.","journal-title":"J Infect Dis"},{"key":"5151_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/COH.0b013e32832a9a17","volume":"44","author":"H Coovadia","year":"2009","unstructured":"Coovadia H. Current issues in prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS. 2009;44:319\u201324.","journal-title":"Curr Opin HIV AIDS."},{"key":"5151_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/511433","volume":"1955","author":"TS Flys","year":"2007","unstructured":"Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;1955:711\u20135.","journal-title":"J Infect Dis"},{"key":"5151_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1089\/aid.2013.0140","volume":"299","author":"HD Ndiaye","year":"2013","unstructured":"Ndiaye HD, Tchiakpe E, Vidal N, Ndiaye O, Diop AK, Peeters M, Mboup S, Toure-Kane C. HIV type 1 subtype C remains the predominant subtype in men having sex with men in Senegal. AIDS Res Hum Retroviruses. 2013;299:1265\u201372.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"5151_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/QAI.0b013e3181af70a4","volume":"522","author":"HD Ndiaye","year":"2009","unstructured":"Ndiaye HD, Toure-Kane C, Vidal N, Niama FR, Niang-Diallo PA, Dieye T, Gaye-Diallo A, Wade AS, Peeters M, Mboup S. Surprisingly high prevalence of subtype C and specific HIV-1 subtype\/CRF distribution in men having sex with men in Senegal. J Acquir Immune Defic Syndr. 2009;522:249\u201352.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5151_CR36","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1089\/aid.2009.0295","volume":"2610","author":"H Diop-Ndiaye","year":"2010","unstructured":"Diop-Ndiaye H, Toure-Kane C, Leye N, Ngom-Gueye NF, Montavon C, Peeters M, Mboup S. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res Hum Retroviruses. 2010;2610:1133\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"5151_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","volume":"192","author":"J Hemelaar","year":"2019","unstructured":"Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B, Gouws-Williams E, Ghys PD. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019;192:143\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"5151_CR38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1099\/0022-1317-82-5-1095","volume":"82","author":"E Baldrich-Rubio","year":"2001","unstructured":"Baldrich-Rubio E, Anagonou S, Stirrups K, Lafia E, Candotti D, Lee H, Allain JP. A complex human immunodeficiency virus type 1 A\/G\/J recombinant virus isolated from a seronegative patient with AIDS from Benin, West Africa. J Gen Virol. 2001;82(5):1095\u2013106.","journal-title":"J Gen Virol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05151-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05151-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:05:23Z","timestamp":1723154723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05151-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5151"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05151-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22911\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22911\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22911\/v1","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"18 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical clearance was obtained from National Ethics Committee for Health Research (CNERS): number 33 of august 09, 2017. Written informed consent was obtained from each study participants. Confidentiality and anonymity of the information was also maintained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}